Actonel Tablet, Film Coated
Product Images NDC 0430-0472

12 FDA label images from Allergan, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Actonel (NDC 0430-0472). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Actonel (risedronate Sodium) Tablets Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Actonel Tablet For Oral Administration Contains The Equivalent Of 5, 30, 35, 75, Or 150 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. The Chemical Structure Of Risedronate Sodium Hemi-pentahydrate Is The Following: (Actonel 01)

Actonel (risedronate Sodium) Tablets Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Actonel Tablet For Oral Administration Contains The Equivalent Of 5, 30, 35, 75, Or 150 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. The Chemical Structure Of Risedronate Sodium Hemi-pentahydrate Is The Following: (Actonel 01)
Chemical structure of the active ingredient in Actonel, showing a pyridine ring attached to a phosphate group with sodium and water molecules indicated as part of the compound.*
FDA Label Image

Figure 1nonvertebral Osteoporosis-related Fractures Cumulative Incidence Over 3 Years Combined Vert Mn And Vert Na (Actonel 02)

Figure 1nonvertebral Osteoporosis-related Fractures Cumulative Incidence Over 3 Years Combined Vert Mn And Vert Na (Actonel 02)
A bar chart comparing the percentage of patients with fractures at different body sites between placebo and Actonel 5 mg groups. The chart shows data for All fractures, Wrist, Humerus, Hip, Pelvis, Leg, and Clavicle, with separate bars for placebo and Actonel 5 mg for each category.*
FDA Label Image

Figure 2change In Bmd From Baseline2-year Prevention Study (Actonel 03)

Figure 2change In Bmd From Baseline2-year Prevention Study (Actonel 03)
A bar chart comparing the mean percentage change in Bone Mineral Density (BMD) with standard error (SE) across three anatomical sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. The chart contrasts results for placebo and Actonel 5 mg groups, with sample sizes (n) indicated for each site and treatment group.*
FDA Label Image

Figure 3change In Bmd From Baselinepatients Recently Initiatingglucocorticoid Therapy (Actonel 04)

Figure 3change In Bmd From Baselinepatients Recently Initiatingglucocorticoid Therapy (Actonel 04)
A bar chart comparing the mean percent change in bone mineral density (BMD) at three anatomical sites: lumbar spine, femoral neck, and femoral trochanter. The chart contrasts the results for placebo versus Actonel 5 mg treatment, showing the number of subjects (n) for each group at each site.*
FDA Label Image

Figure 4change In Bmd From Baselinepatients On Long-termglucocorticoid Therapy (Actonel 05)

Figure 4change In Bmd From Baselinepatients On Long-termglucocorticoid Therapy (Actonel 05)
A bar chart comparing the mean percentage change in bone mineral density (BMD) ± standard error in three anatomical sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. The chart contrasts Placebo and Actonel 5 mg groups, showing sample sizes for each group and site.*
FDA Label Image

Figure 5incidence Of Vertebral Fractures In Patientsinitiating Or Continuing Glucocorticoid Therapy (Actonel 06)

Figure 5incidence Of Vertebral Fractures In Patientsinitiating Or Continuing Glucocorticoid Therapy (Actonel 06)
A bar chart comparing the incidence percentage for placebo and ACTONEL 5 mg in three patient groups: those continuing glucocorticoid treatment, those initiating glucocorticoid treatment, and a combined group. The chart labels number of patients (n) for each treatment and group.*
FDA Label Image

Figure 6mean Percent Change From Baseline Inserum Alkaline Phosphatase Excess By Visit (Actonel 07)

Figure 6mean Percent Change From Baseline Inserum Alkaline Phosphatase Excess By Visit (Actonel 07)
A line graph comparing the percentage change over visit days between DIDRONEL 400 mg and ACTONEL 30 mg. The x-axis represents visit days grouped into Treatment, Follow-Up, and Extended Follow-Up periods, while the y-axis shows percentage change with measurements and sample sizes noted. The graph includes error bars reflecting variability in the data.*
FDA Label Image

Rx Onlyndc 0430-0471-15actonel(risedronate Sodium) Tablets5 mg30 Tablets (Actonel 08)

Rx Onlyndc 0430-0471-15actonel(risedronate Sodium) Tablets5 mg30 Tablets (Actonel 08)
Actonel 5 mg (risedronate sodium) tablets packaging label displaying the product name, strength, dosage form, quantity of 30 tablets, NDC 0430-0471-15, and the labeler Allergan, Inc. The label instructs to dispense the enclosed medication guide to each patient.*
FDA Label Image

Rx Onlyndc 0430-0470-15actonel(risedronate Sodium) Tablets30 mg30 Tablets (Actonel 09)

Rx Onlyndc 0430-0470-15actonel(risedronate Sodium) Tablets30 mg30 Tablets (Actonel 09)
Actonel 30 mg (risedronate sodium) tablets label showing 30 tablets per package. The label includes the NDC 0430-0470-15 and instructions to dispense the enclosed Medication Guide to each patient. The labeler is Allergan, Inc.*
FDA Label Image

Ndc 0430-0472-034 Week Supply(4 Tablets)dispense The Enclosed Medication Guide To Each Patientactonel®(risedronate Sodium) Tablets35 mgonce-a-week4 Tablets (Actonel 0a)

Ndc 0430-0472-034 Week Supply(4 Tablets)dispense The Enclosed Medication Guide To Each Patientactonel®(risedronate Sodium) Tablets35 mgonce-a-week4 Tablets (Actonel 0a)
Packaging label for Actonel 35 mg (risedronate sodium) tablets by Allergan, Inc. The label indicates a 4-week supply containing 4 tablets for once-a-week use. It includes the product name, strength, dosage form, and instruction to dispense the enclosed Medication Guide to each patient. The NDC number 0430-0472-03 is visible on the label.*
FDA Label Image

Ndc 0430-0477-02actonel(risedronate Sodium) Tablets75 mgone Month Pack(2 Tablets)rx Only (Actonel 0b)

Ndc 0430-0477-02actonel(risedronate Sodium) Tablets75 mgone Month Pack(2 Tablets)rx Only (Actonel 0b)
Actonel 35 mg (risedronate sodium) tablets packaging label for a 12-week supply. The label includes the product name, strength, active ingredient, dosage form, and directions to dispense the enclosed Medication Guide to each patient. The labeler is Allergan, Inc.*
FDA Label Image

Ndc 0430-0478-01one Month Pack(1 Tablet)dispense The Enclosed Medication Guide To Each Patientactonel®(risedronate Sodium) Tablets150 mgonce-a-month1 Tablet (Actonel 0c)

Ndc 0430-0478-01one Month Pack(1 Tablet)dispense The Enclosed Medication Guide To Each Patientactonel®(risedronate Sodium) Tablets150 mgonce-a-month1 Tablet (Actonel 0c)
Actonel 75 mg tablets one month pack containing 2 tablets. The label includes dosing instructions to take tablets on two consecutive days each month, with emphasis on swallowing the tablet whole with 6 to 8 ounces of plain water on the first day, and repeating the same on the second day. The labeler is Allergan, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.